NYSE$CHE
Chemed Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Chemed's Q1 2024 performance was marked by revenue growth and increased EPS, with VITAS Healthcare driving revenue while Roto-Rooter faced revenue decline.
Chemed Corporation reported a 5.2% increase in revenue to $589.2 million and a GAAP diluted EPS of $4.24, up 18.4%. Adjusted diluted EPS increased by 21.5% to $5.20. VITAS Healthcare saw a 14.0% increase in net patient revenue, while Roto-Rooter experienced a 5.8% decrease in revenue.
- Consolidated revenue increased by 5.2% to $589.2 million.
- GAAP diluted EPS rose by 18.4% to $4.24.
- VITAS Healthcare's net patient revenue increased by 14.0%.
- Roto-Rooter's revenue decreased by 5.8%.
Headline financials
Revenue & EPS history
Chemed · Revenue · Quarterly
$589M
Revenue by segment
Chemed · $565M total across 2 segments · Q3 2023
- VITAS Healthcare$334M+12.4%59.1%
- Roto-Rooter$231M+0.3%40.9%
Forward guidance
Management reiterates its estimated full-year 2024 earnings per diluted share guidance range of $23.30 to $23.70, excluding certain items, and anticipates providing updated 2024 earnings guidance and related subsidiary operating metrics as part of the June 30, 2024 earnings press release.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.7%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+2.1%
Avg return
30 days after
53%
36 / 68 earnings
Positive
+13.0%
Q3 2015
Best reaction
-14.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -0.1% | +4.0% | |
| Q4 2025 | -14.8% | -9.1% | -21.0% | |
| Q3 2025 | +6.0% | +0.4% | +0.1% | |
| Q1 2025 | -6.6% | -1.8% | -2.7% | |
| Q4 2024 | +7.4% | +7.7% | +11.0% | |
| Q3 2024 | -12.0% | -12.7% | -6.2% | |
| Q2 2024 | -0.1% | +2.4% | +5.7% | |
| Q1 2024 | -7.0% | -8.1% | -9.9% | |
| Q4 2023 | +5.1% | +2.6% | +7.3% | |
| Q3 2023 | +9.3% | +10.9% | +14.4% | |
| Q2 2023 | -8.1% | -8.0% | -10.8% | |
| Q1 2023 | -3.7% | -2.2% | -4.1% | |
| Q4 2022 | +3.3% | +1.7% | +1.9% | |
| Q3 2022 | +3.2% | +4.1% | +12.6% | |
| Q2 2022 | -6.8% | -9.2% | -8.3% | |
| Q1 2022 | -1.4% | -1.0% | +0.8% | |
| Q4 2021 | +5.1% | +5.8% | +3.8% | |
| Q3 2021 | +9.2% | +9.0% | +9.4% | |
| Q2 2021 | -4.4% | -0.4% | -2.4% | |
| Q1 2021 | +1.5% | +2.3% | +6.1% | |
| Q4 2020 | -0.8% | -6.7% | -3.9% | |
| Q3 2020 | +1.2% | +3.5% | +0.2% | |
| Q2 2020 | +9.0% | +10.3% | +12.2% | |
| Q1 2020 | -3.9% | -6.5% | +5.6% | |
| Q4 2019 | +3.2% | -1.2% | -23.1% | |
| Q3 2019 | -1.7% | +0.6% | +5.9% | |
| Q2 2019 | +3.7% | +8.1% | +13.9% | |
| Q1 2019 | -0.6% | +0.7% | +0.3% | |
| Q4 2018 | +1.3% | +2.8% | +1.9% | |
| Q3 2018 | +6.2% | +6.6% | +7.6% | |
| Q2 2018 | +0.4% | -2.5% | +0.1% | |
| Q1 2018 | +3.0% | +3.3% | +13.4% | |
| Q4 2017 | +2.4% | +2.1% | +12.9% | |
| Q3 2017 | +9.1% | +5.0% | +12.7% | |
| Q2 2017 | -1.1% | -2.3% | -6.3% | |
| Q1 2017 | +10.0% | +9.4% | +9.0% | |
| Q4 2016 | +1.9% | +2.0% | +9.1% | |
| Q3 2016 | -0.3% | +1.8% | +6.3% | |
| Q2 2016 | +5.0% | +3.0% | -7.9% | |
| Q1 2016 | -6.7% | — | — | |
| Q4 2015 | -5.6% | — | — | |
| Q3 2015 | +13.0% | — | — | |
| Q2 2015 | +5.1% | — | — | |
| Q1 2015 | -4.7% | — | — | |
| Q4 2014 | +7.5% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | +4.3% | — | — | |
| Q1 2014 | -3.3% | — | — | |
| Q4 2013 | +10.5% | — | — | |
| Q3 2013 | -5.2% | — | — | |
| Q2 2013 | -7.3% | — | — | |
| Q1 2013 | +3.4% | — | — | |
| Q4 2012 | +4.9% | — | — | |
| Q3 2012 | -2.0% | — | — | |
| Q2 2012 | +5.1% | — | — | |
| Q1 2012 | +2.9% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q2 2011 | -5.8% | — | — | |
| Q1 2010 | -2.6% | — | — | |
| Q1 2011 | +1.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +1.4% | — | — | |
| Q3 2010 | +1.4% | — | — | |
| Q2 2010 | -0.9% | — | — | |
| Q2 2009 | -0.9% | — | — | |
| Q4 2009 | -0.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro